Abiomed - ABMD Stock Forecast, Price & News

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Abiomed Price Performance

Shares of ABMD Stock opened at $293.59 on Friday. The firm has a market cap of $13.40 billion, a PE ratio of 61.94 and a beta of 1.35. The company has a 50-day moving average of $265.06 and a two-hundred day moving average of $282.70. Abiomed has a 1-year low of $219.85 and a 1-year high of $379.30.

Abiomed (NASDAQ:ABMD - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.19. The business had revenue of $277.15 million for the quarter, compared to analysts' expectations of $276.46 million. Abiomed had a net margin of 20.60% and a return on equity of 14.33%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.10 earnings per share. Sell-side analysts anticipate that Abiomed will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Abiomed from $410.00 to $355.00 in a report on Thursday, July 21st. StockNews.com lowered shares of Abiomed from a "buy" rating to a "hold" rating in a report on Friday, July 1st. Finally, Morgan Stanley dropped their target price on shares of Abiomed from $275.00 to $235.00 and set an "underweight" rating for the company in a report on Friday, July 15th.

Insider Transactions at Abiomed

In other news, Director Martin P. Sutter sold 2,000 shares of the stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $258.01, for a total transaction of $516,020.00. Following the sale, the director now owns 128,390 shares of the company's stock, valued at $33,125,903.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Martin P. Sutter sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $258.01, for a total value of $516,020.00. Following the sale, the director now owns 128,390 shares of the company's stock, valued at $33,125,903.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Todd A. Trapp sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $300.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief financial officer now directly owns 16,927 shares in the company, valued at approximately $5,078,100. The disclosure for this sale can be found here. Corporate insiders own 2.50% of the company's stock.